Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
US Market

Monte Rosa Therapeutics (GLUE) Financial Statements

203 Followers

Monte Rosa Therapeutics Financial Overview

Monte Rosa Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.527; its P/E ratio is -1.85; Monte Rosa Therapeutics is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is $-0.53. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 1.06M$ 397.00K---
Gross Profit$ 1.06M$ 397.00K---
EBIT$ -31.89M$ -32.76M$ -36.97M$ -34.73M$ -34.12M
EBITDA$ -29.99M$ -30.94M$ -35.13M-$ -32.92M
Net Income Common Stockholders$ -31.97M$ -33.25M$ -34.88M$ -35.18M$ -31.68M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 192.89M$ 232.41M$ 178.48M$ 203.07M$ 232.69M
Total Assets$ 266.75M$ 303.75M$ 252.10M$ 278.62M$ 309.03M
Total Debt$ 45.18M$ 46.04M$ 46.40M$ 47.03M$ 46.16M
Net Debt$ -147.71M$ -186.37M$ -132.08M$ -156.03M$ -186.53M
Total Liabilities$ 114.23M$ 124.50M$ 67.58M$ 64.96M$ 65.30M
Stockholders Equity$ 152.52M$ 179.25M$ 184.52M$ 213.61M$ 243.73M
Cash Flow-
Free Cash Flow$ -39.55M$ 27.95M$ -26.36M-$ -32.54M
Operating Cash Flow$ -38.16M$ 29.63M$ -24.71M-$ -23.36M
Investing Cash Flow$ 9.85M$ 14.30M$ 35.63M-$ 20.33M
Financing Cash Flow$ 246.00K$ 25.17M$ 1.10M-$ 18.00K
Currency in USD

Monte Rosa Therapeutics Earnings and Revenue History

Monte Rosa Therapeutics Debt to Assets

Monte Rosa Therapeutics Cash Flow

Monte Rosa Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis